Summary by Moomoo AI
Nikko Asset Management Americas, Inc. has filed an amendment to its Schedule 13G with the United States Securities and Exchange Commission, indicating a change in its holdings of CRISPR Therapeutics AG. As of December 31, 2023, Nikko Asset Management Americas, Inc. reported shared voting power over 3,050,548 common shares and shared dispositive power over 3,369,762 common shares, representing 4.24% of the company's class of securities. This filing, dated February 12, 2024, and signed by Chief Compliance Officer Gary L. Beckham, certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The filing also notes that the securities are beneficially owned by Nikko Asset Management Americas, Inc.'s parent holding companies, Sumitomo Mitsui Trust Holdings Inc. and Nikko Asset Management Co., Ltd.